2008 HAPPI Interview

Garth Fisher M.D.® F.A.C.S.
Board Certified Plastic Surgeon
Beverly Hills, California USA

CellCeuticals® Skin Care Inc
Cofounder and Chairman

Biomedical Skin Treatment Institute®
Founder and Director

1. What specific skin conditions nullify a potential patient for cosmetic surgery?

A- Beautiful skin will enhance the results of almost any cosmetic surgery procedure. There are definitely patients who can eliminate or delay the need for more invasive procedures by improving the quality of their skin! Traditional procedures such as facelifts, browlifts, and eyelid surgery among others, remove excess skin and shift tissue to a more youthful location. They cannot however, improve the quality of the skin. (Tone, firmness, radiance, elasticity, texture, density, smoothness, pigmentation, hydration, pore size etc) Laser procedures, dermabrasion, and chemical peels can change the quality of the skin, but with not insignificant risk, cost, and downtime. I always try to advise the least invasive, least expensive, and least risky option first to my patients to help satisfy their needs. Effective skin care products are part of this philosophy! Of course there are higher risk patients including those with darker pigmented skin as well as medical problems such as diabetes that have to be even more careful considering invasive procedures.

Some patients with thin crepe skin around the lower eyelids really benefit from effective skin care treatments that can actually thicken the skin in this area! The increased density of tissue really helps improve the appearance of their eyes! In many cases, patients with skin fitting this description are better suited for skin care products than cosmetic surgery.

2. What other beauty products and/or beauty companies Paul Scott Premo work for prior helming CellCeuticals?

Allergan, Chanel, MD Formulations/ MD Forte, Murad, and Redken

3. Regarding the bioengineered lipopeptides that are part of your GFP Cellular Complex - what is their ingredient origin?

A. The growth factor lipopeptides are synthesized. In vitro tests demonstrate the two proprietary sequences upregulate matrix protein synthesis (collagen) while down regulating inflammatory enzymes e.g. MMPs (matrix metalloproteases).

4. Is the GFP Complex present in each product in the CellCeuticals line?

The GFP Cellular Complex is exclusively in the CellGenesis Regenerative Skin Treatment, which performs as a cellular stimulant to encourage cellular regeneration.

5. What other beneficial ingredients are used in your formulation?

Retinol and antioxidant complex delivered via a proprietary nanoemulsion delivery system, which allows targeted and sustainable delivery of bioactives. In addition, the CellCeuticals Skin Treatment System has been carefully formulated and undergone rigorous testing to substantiate both product performance and safety e.g. dermatologist, ophthalmologist and irritancy testing. Moreover, we have eliminated ingredients that consumers do not want in personal products such as parabens, SLS and other controversial ingredients.

6. How long were the products in development prior to launching?

The CellCeuticals GFP Cellular Complex is the culmination of 12 to 15 years of research in new states of matter and delivery technologies designed to target cellular skin aging. The products have undergone development for two years.

7. Please tell me more about the clinical study - how many participants took part in the study? What exactly was studied?

A. CellCeuticals Skin Care, Inc. initiated two 8-week independent and objective clinical studies with 70 subjects having mild to moderate periocular fine lines and wrinkles and the presence of mild to moderate dyschromia. Results of the first 8-week clinical trial show that the CellCeuticals Biomedical Skin Treatments test regimen [consisting of CellGenesis Regenerative Skin Treatment, Extreme Defense Anti-Cell Damage Skin Treatment, and Extremely Gentle Skin Cleanser, is an effective treatment regimen for reducing the appearance of fine lines and wrinkles and improving skin radiance, smoothness, texture, tone, discoloration (dyschromia), firmness, and density. Significant improvements in all clinical grading parameters were seen as early as week 2. After eight weeks of usage, the regimen produced the following percent changes in various clinical parameters:

36.7% improvement in visible wrinkles
14.4% improvement in the appearance of coarse wrinkles
63.9% improvement in skin smoothness
31.4% improvement in the appearance of skin texture
33.0% improvement in skin radiance
24.9% improvement in skin tone
20.2% improvement in skin firmness
13.0%-15.8% improvement in skin discoloration (dyschromia)

Bioinstrumentation measurements showed the regimen produced a 48.2% increase in skin hydration (Corneometer), a 26.8% increase in skin density (ultrasound measurements) and a 20.2% improvement in skin firmness (i.e., decreased extensibility, measured by Cutometer) by Week 8. The combination of Corneometer, ultrasound, and Cutometer data suggests that the regimen remodels photodamaged skin so that the skin appears firmer, denser, and more hydrated.

Image analysis of replica impressions showed significant improvements in lines and wrinkles at the week 4 and week 8 visits. Deepest wrinkle depth decreased by 45.7%, while largest wrinkle area decreased by 56.8%. At all study visits, irritation/safety grading showed significant improvements in erythema (skin redness) and skin tightness. Erythema was reduced 87.2% at the week 8 visit. There was no significant worsening of other irritation/safety parameters at any of the study visits. Results of the self-assessment questionnaires (positive versus negative responses) show the regimen was very well received by subjects.

Self-assessment questionnaires reported 100% of subjects agreed their skin was smoother, 93% agreed skin felt more elastic, 83% agreed fine lines and wrinkles appeared minimized, 86% agreed skin looked clearer, and 90% agreed skin looked healthier.

8. Where are CellCeuticals products sold?

The CellCeuticlals Biomedical Skin Treatments collection will be available January 2009, and distributed through a multi -channel distribution strategy beginning with direct response television and e-commerce at the company's website www.cellceuticalskincare.com. National and international retail distribution is planned for 2010.